Post-merg­er, gene ther­a­py play­er Ad­verum makes Am­ber Salz­man CEO, de­lays a clin­i­cal tri­al start

Avalanche Biotech­nolo­gies’ ac­qui­si­tion of Paris-based An­na­pur­na and their merg­er in­to a new gene ther­a­py com­pa­ny called Ad­verum Biotech­nolo­gies $AD­VM is still play­ing out.

Five months af­ter the two biotechs an­nounced the deal, for­mer An­na­pur­na CEO Am­ber Salz­man is step­ping up to the CEO’s job, and one of her first acts as chief is de­lay­ing the start of a key tri­al by a year. Paul Cleve­land, mean­while, is step­ping up to the ex­ec­u­tive chair­man’s post in the quick re­arrange­ment of ti­tles.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.